Historical review of thymosin α 1 in infectious diseases

Roberto Camerini, Enrico Garaci

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

INTRODUCTION: Thymosin α 1 (Tα1) is a peptidic biological response modifier, which plays a significant role in activating and regulating various cells of the immune system. For the above-mentioned activities it is expected to exert a clinical benefit in the treatment of diseases where the immune system is altered.

AREAS COVERED: Several clinical trials have been carried out with Tα1 for treatment or prevention of many different infectious diseases such as hepatitis B and C, sepsis and Aspergillosis in bone marrow-transplanted patients. Data available on the use of Tα1 in infectious disease as well as a vaccine enhancer will be reviewed to possibly generate new working hypothesis.

EXPERT OPINION: Tα1 has been widely used in thousands of patients. Nevertheless, there are some issues that have not yet been properly addressed (i.e., dose, schedule, combination treatments, end-points to be evaluated in clinical trials). In the most recent clinical trials Tα1 has been used at higher doses than those commonly used in the past showing a direct proportionality between the dose and the effect. The safety profile of Tα1 is excellent and it is virtually devoid of toxicity.

Original languageEnglish
Pages (from-to)S117-S127
JournalExpert Opinion on Biological Therapy
Volume15
DOIs
Publication statusPublished - 2015

Fingerprint

Thymosin
Communicable Diseases
Immune system
Clinical Trials
Aspergillosis
Immune System Diseases
Immunologic Factors
Hepatitis C
Hepatitis B
Toxicity
Immune System
Sepsis
Appointments and Schedules
Bone
Therapeutics
Vaccines
Bone Marrow
Safety

Keywords

  • immune modulation
  • immune system
  • infectious diseases
  • thymosin α 1
  • vaccine enhancer

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Historical review of thymosin α 1 in infectious diseases. / Camerini, Roberto; Garaci, Enrico.

In: Expert Opinion on Biological Therapy, Vol. 15, 2015, p. S117-S127.

Research output: Contribution to journalArticle

@article{51336991e84a4c79aad8f61b986fa538,
title = "Historical review of thymosin α 1 in infectious diseases",
abstract = "INTRODUCTION: Thymosin α 1 (Tα1) is a peptidic biological response modifier, which plays a significant role in activating and regulating various cells of the immune system. For the above-mentioned activities it is expected to exert a clinical benefit in the treatment of diseases where the immune system is altered.AREAS COVERED: Several clinical trials have been carried out with Tα1 for treatment or prevention of many different infectious diseases such as hepatitis B and C, sepsis and Aspergillosis in bone marrow-transplanted patients. Data available on the use of Tα1 in infectious disease as well as a vaccine enhancer will be reviewed to possibly generate new working hypothesis.EXPERT OPINION: Tα1 has been widely used in thousands of patients. Nevertheless, there are some issues that have not yet been properly addressed (i.e., dose, schedule, combination treatments, end-points to be evaluated in clinical trials). In the most recent clinical trials Tα1 has been used at higher doses than those commonly used in the past showing a direct proportionality between the dose and the effect. The safety profile of Tα1 is excellent and it is virtually devoid of toxicity.",
keywords = "immune modulation, immune system, infectious diseases, thymosin α 1, vaccine enhancer",
author = "Roberto Camerini and Enrico Garaci",
year = "2015",
doi = "10.1517/14712598.2015.1033393",
language = "English",
volume = "15",
pages = "S117--S127",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Taylor and Francis Ltd.",

}

TY - JOUR

T1 - Historical review of thymosin α 1 in infectious diseases

AU - Camerini, Roberto

AU - Garaci, Enrico

PY - 2015

Y1 - 2015

N2 - INTRODUCTION: Thymosin α 1 (Tα1) is a peptidic biological response modifier, which plays a significant role in activating and regulating various cells of the immune system. For the above-mentioned activities it is expected to exert a clinical benefit in the treatment of diseases where the immune system is altered.AREAS COVERED: Several clinical trials have been carried out with Tα1 for treatment or prevention of many different infectious diseases such as hepatitis B and C, sepsis and Aspergillosis in bone marrow-transplanted patients. Data available on the use of Tα1 in infectious disease as well as a vaccine enhancer will be reviewed to possibly generate new working hypothesis.EXPERT OPINION: Tα1 has been widely used in thousands of patients. Nevertheless, there are some issues that have not yet been properly addressed (i.e., dose, schedule, combination treatments, end-points to be evaluated in clinical trials). In the most recent clinical trials Tα1 has been used at higher doses than those commonly used in the past showing a direct proportionality between the dose and the effect. The safety profile of Tα1 is excellent and it is virtually devoid of toxicity.

AB - INTRODUCTION: Thymosin α 1 (Tα1) is a peptidic biological response modifier, which plays a significant role in activating and regulating various cells of the immune system. For the above-mentioned activities it is expected to exert a clinical benefit in the treatment of diseases where the immune system is altered.AREAS COVERED: Several clinical trials have been carried out with Tα1 for treatment or prevention of many different infectious diseases such as hepatitis B and C, sepsis and Aspergillosis in bone marrow-transplanted patients. Data available on the use of Tα1 in infectious disease as well as a vaccine enhancer will be reviewed to possibly generate new working hypothesis.EXPERT OPINION: Tα1 has been widely used in thousands of patients. Nevertheless, there are some issues that have not yet been properly addressed (i.e., dose, schedule, combination treatments, end-points to be evaluated in clinical trials). In the most recent clinical trials Tα1 has been used at higher doses than those commonly used in the past showing a direct proportionality between the dose and the effect. The safety profile of Tα1 is excellent and it is virtually devoid of toxicity.

KW - immune modulation

KW - immune system

KW - infectious diseases

KW - thymosin α 1

KW - vaccine enhancer

UR - http://www.scopus.com/inward/record.url?scp=84965089221&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84965089221&partnerID=8YFLogxK

U2 - 10.1517/14712598.2015.1033393

DO - 10.1517/14712598.2015.1033393

M3 - Article

C2 - 26098768

AN - SCOPUS:84965089221

VL - 15

SP - S117-S127

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

ER -